or Try an Advanced Search...

    Glucagon Like Peptide 1 Stocks List

    Symbol Grade Name % Change
    THNR F Amplify Weight Loss Drug & Treatment ETF 0.94
    ORMP D Oramed Pharmaceuticals Inc. 1.30
    NVO D Novo Nordisk A/S 2.37
    VANI D Vivani Medical, Inc. 0.75
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Glucagon Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones Implant Inflammation Integrated Security Life Sciences

    Related ETFs - A few ETFs which own one or more of the above listed Glucagon Like Peptide 1 stocks.

    Symbol Grade Name Weight
    OZEM F Roundhill GLP-1 & Weight Loss ETF 17.04
    THNR F Amplify Weight Loss Drug & Treatment ETF 13.26
    PPH D Market Vectors Pharmaceutical ETF 7.69
    BELT B BlackRock Long-Term U.S. Equity ETF 5.18
    AADR A WCM BNY Mellon Focused Growth ADR ETF 4.85
    View all Glucagon Like Peptide 1 ETFs...
    Compare ETFs
    Compare BELT to AADR Compare OZEM to THNR Compare PPH to BELT

        Glucagon Like Peptide 1 Stocks Recent News

        Date Stock Title
        Nov 22 NVO “No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
        Nov 22 NVO Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock
        Nov 22 NVO Barclays says buy Novo Nordisk stock 'into this critically important catalyst'
        Nov 22 NVO RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?
        Nov 22 NVO Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens
        Nov 22 NVO Oura rings to track blood sugar, Vaccines vs RFK Jr., and Ozempic 2.0: Pharma news roundup
        Nov 21 NVO The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
        Nov 21 NVO Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
        Nov 21 NVO Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
        Nov 21 NVO Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
        Nov 20 NVO More companies covering weight loss drugs for their employees
        Nov 20 NVO Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
        Nov 20 NVO Is Novo Nordisk Stock a Buy Right Now?
        Nov 20 NVO RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
        Nov 19 NVO Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints
        Nov 19 NVO Sector Update: Health Care Stocks Decline
        Nov 19 NVO Novo Nordisk Unusual Options Activity For November 19
        Nov 19 NVO Sector Update: Health Care Stocks Mixed Tuesday Afternoon
        Nov 19 NVO Novo Erases 2024 Gain, Wiping Out $210 Billion in Value
        Nov 19 NVO Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Glucagon Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones Implant Inflammation Integrated Security Life Sciences
        Glucagon Like Peptide 1

        Glucagon-like peptide 1 (GLP-1) is a hormone that is produced in the gut and released in response to food intake. It stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety. GLP-1 is a key regulator of glucose homeostasis and is used as a treatment for type 2 diabetes.

        Browse All Tags